ANI Retained Earnings vs Short Long Term Debt Total Analysis
ANIP Stock | USD 61.43 2.34 3.67% |
ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Retained Earnings and its Short Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.
Retained Earnings vs Short Long Term Debt Total
Retained Earnings vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Retained Earnings account and Short Long Term Debt Total. At this time, the significance of the direction appears to have very week relationship.
The correlation between ANI Pharmaceuticals' Retained Earnings and Short Long Term Debt Total is 0.26. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Retained Earnings and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of ANI Pharmaceuticals are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Retained Earnings i.e., ANI Pharmaceuticals' Retained Earnings and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.26 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Short Long Term Debt Total
Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.As of 05/18/2024, Selling General Administrative is likely to grow to about 157.9 M, while Discontinued Operations is likely to drop slightly above 156 K.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 115.5M | 177.6M | 245.5M | 257.8M | Total Revenue | 216.1M | 316.4M | 486.8M | 511.2M |
ANI Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
ANI Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ANI Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 456.8M | 461.2M | 771.6M | 760.1M | 904.4M | 949.6M | |
Other Current Liab | 36.7M | 54.0M | 63.6M | 69.3M | 99.8M | 104.8M | |
Total Current Liabilities | 61.7M | 78.6M | 87.5M | 99.4M | 145.5M | 152.8M | |
Total Stockholder Equity | 212.8M | 195.7M | 358.7M | 338.5M | 432.7M | 454.4M | |
Property Plant And Equipment Net | 40.6M | 41.3M | 52.7M | 43.2M | 44.6M | 46.8M | |
Net Debt | 123.4M | 177.8M | 187.1M | 238.3M | 94.2M | 98.9M | |
Retained Earnings | 17.6M | (5.0M) | (47.8M) | (97.3M) | (80.1M) | (84.1M) | |
Accounts Payable | 14.6M | 11.3M | 23.0M | 29.3M | 36.7M | 38.5M | |
Cash | 62.3M | 7.9M | 100.3M | 48.2M | 221.1M | 232.2M | |
Non Current Assets Total | 269.1M | 290.9M | 449.8M | 415.8M | 384.8M | 404.0M | |
Cash And Short Term Investments | 62.3M | 7.9M | 100.3M | 48.2M | 221.1M | 232.2M | |
Common Stock Shares Outstanding | 12.0M | 12.0M | 12.6M | 16.3M | 18.2M | 19.1M | |
Liabilities And Stockholders Equity | 456.8M | 461.2M | 771.6M | 760.1M | 904.4M | 949.6M | |
Other Current Assets | 5.1M | 5.9M | 11.3M | 8.4M | 25.2M | 26.5M | |
Total Liab | 244.0M | 265.5M | 412.9M | 421.5M | 471.7M | 495.3M | |
Property Plant And Equipment Gross | 40.6M | 41.3M | 75.6M | 76.0M | 77.5M | 81.4M | |
Total Current Assets | 187.7M | 170.3M | 321.8M | 344.3M | 519.6M | 545.6M | |
Other Stockholder Equity | 200.1M | 212.1M | 384.7M | 398.8M | 479.2M | 503.1M | |
Accumulated Other Comprehensive Income | (4.9M) | (11.4M) | (3.1M) | 12.2M | 8.9M | 9.3M | |
Short Long Term Debt Total | 185.7M | 185.7M | 287.4M | 286.5M | 315.3M | 331.1M | |
Short Term Debt | 115.7M | 9.9M | 13.2M | 850K | 977.5K | 928.6K | |
Current Deferred Revenue | 451K | 80K | 87K | 8.2M | 9.4M | 9.9M | |
Non Currrent Assets Other | 1.2M | 802K | 2.2M | 2.6M | 6.1M | 6.4M | |
Non Current Liabilities Total | 182.3M | 186.9M | 325.3M | 322.1M | 326.2M | 342.5M | |
Net Receivables | 72.1M | 95.8M | 128.5M | 165.4M | 162.1M | 170.2M | |
Net Tangible Assets | 28.8M | 3.6M | 36.7M | 58.7M | 52.8M | 55.5M | |
Other Assets | 44.6M | 57.5M | 75.1M | 92.7M | 106.6M | 112.0M | |
Long Term Debt | 175.8M | 172.4M | 286.5M | 285.7M | 284.8M | 149.2M | |
Retained Earnings Total Equity | 17.6M | (5.0M) | (47.8M) | (97.3M) | (111.9M) | (117.5M) | |
Inventory | 48.2M | 60.8M | 81.7M | 105.4M | 111.2M | 116.8M | |
Deferred Long Term Liab | 1.5M | 800K | 500K | 600K | 690K | 458.1K | |
Intangible Assets | 180.4M | 188.5M | 294.1M | 251.6M | 209.0M | 156.5M | |
Property Plant Equipment | 40.6M | 41.3M | 52.7M | 43.2M | 49.7M | 52.2M | |
Capital Surpluse | 200.8M | 214.4M | 387.8M | 403.9M | 464.5M | 237.5M | |
Other Liab | 7K | 201K | 31.0M | 35.1M | 40.3M | 42.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 13.824 | Earnings Share 1.61 | Revenue Per Share 27.705 | Quarterly Revenue Growth 0.287 | Return On Assets 0.0391 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.